CGENCompugen Ltd.
The Read
CGEN shares dropped about 27% after Q1 2026 earnings missed revenue expectations despite pipeline progress, but then surged over 110% by mid-June 2026 as in-line EPS and promising trial updates fueled strong confidence in its AI-driven immuno-oncology platform.
The schedule
- Thu15Oct
Targeted window for strategic partnership or licensing deal announcements for lead immuno-oncology assets.
- Thu10Dec
Elevated risk window for strategic financing or potential equity dilution to fund 2027 operations.
- Wed3Feb
Q3 2026 earnings release covering late-year clinical execution and remaining 2026 capital.
- Sat15May
Q1 2027 earnings release and early-year clinical milestone review.
Past
- Wed5Aug
Q2 2026 earnings release and clinical pipeline update, focusing on cash runway visibility and early-stage immuno-oncology progress.
- Thu11Jun
Actual outcome: Bull · $2.02 at outcome
Compugen reported in-line EPS of -$0.08 and presented a trial-in-progress poster for its Phase 1 MAIA-ovarian study of COM701 at the ESMO Gynaecological Cancers Congress. Management also showcased its AI-driven target discovery platform in immuno-oncology during industry events. While the stock saw a negligible 1% dip over the immediate event window, shares maintained levels well above the $1.25 bull target, reflecting strong underlying confidence in the company's AI/ML-powered clinical pipeline.
Q4 2026 earnings and full-year 2027 clinical outlook.
- Fri5Jun
Actual outcome: Bull · $2.36 at outcome
Compugen shares rose 8.6% following the event date, driven by continued visibility and progress of its clinical pipeline. The company announced a trial-in-progress poster presentation for its Phase 1 MAIA-ovarian study of COM701 at the ESMO Gynaecological Cancers Congress and participated in an AI/ML drug development fireside chat, which helped maintain positive investor sentiment.
Compugen is expected to present updated clinical data for its lead immuno-oncology programs, including COM701 and potentially COM902, at a major mid-2026 oncology congress; from a $2.00 base, convincingly positive responses or durability data in combination with checkpoint inhibitors could re-rate the stock toward $3.20, while inconclusive or negative safety/efficacy signals could push the shares down toward $3.20.
- Mon18May
Actual outcome: Bear · $2.09 at outcome
Compugen reported a Q1 2026 loss of $0.08 per share, which met EPS estimates but lagged behind revenue expectations. While the company provided reassuring pipeline updates—noting that the COM701 MAIA-ovarian trial is on track for a Q1 2027 interim analysis and AstraZeneca continues to advance partnered programs—the revenue miss and lack of near-term catalysts weighed heavily on shares, driving the stock down 26.9% toward the bear floor.
Q1 2026 earnings and cash runway commentary around $2.69 will be closely watched after an unusually strong 2025 revenue print, with investors focused on the durability of milestone income and how long Compugen can fund COM701/COM902 development without another raise; a clean update and reassuring runway could support a move toward $3.10, while softer revenue or a shorter runway could send the stock back toward $3.10.
